Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: NAMS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $43.53
1 Year Target Price $43.53
| 5 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 46.34% | Avg. Invested days 36 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.08B USD | Price to earnings Ratio - | 1Y Target Price 43.53 |
Price to earnings Ratio - | 1Y Target Price 43.53 | ||
Volume (30-day avg) 9 | Beta -0.03 | 52 Weeks Range 14.06 - 27.29 | Updated Date 06/29/2025 |
52 Weeks Range 14.06 - 27.29 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.84 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2314.47% |
Management Effectiveness
Return on Assets (TTM) -18.15% | Return on Equity (TTM) -31.51% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1276778471 | Price to Sales(TTM) 44.23 |
Enterprise Value 1276778471 | Price to Sales(TTM) 44.23 | ||
Enterprise Value to Revenue 27.08 | Enterprise Value to EBITDA 27.63 | Shares Outstanding 112271000 | Shares Floating 54899238 |
Shares Outstanding 112271000 | Shares Floating 54899238 | ||
Percent Insiders 0.39 | Percent Institutions 112.95 |
Analyst Ratings
Rating 3 | Target Price 43.53 | Buy 4 | Strong Buy 5 |
Buy 4 | Strong Buy 5 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
NewAmsterdam Pharma Company N.V. Ordinary Shares
Company Overview
History and Background
NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company focused on the research and development of transformative therapies for cardio-metabolic diseases, particularly those addressing unmet needs in lipid metabolism. The company was founded to develop and commercialize obicetrapib, a novel oral CETP inhibitor.
Core Business Areas
- Cardio-Metabolic Disease Therapies: Focuses on developing oral therapies for cardio-metabolic diseases such as hypercholesterolemia. Their primary drug candidate is obicetrapib.
Leadership and Structure
The leadership team consists of experienced pharmaceutical executives with expertise in clinical development, regulatory affairs, and commercialization. The organizational structure is typical of a clinical-stage biopharmaceutical company, emphasizing research and development.
Top Products and Market Share
Key Offerings
- Obicetrapib: Obicetrapib is an oral cholesteryl ester transfer protein (CETP) inhibitor being developed to significantly lower LDL-cholesterol levels and reduce cardiovascular risk. It is currently undergoing Phase 3 clinical trials. Market share is currently 0% since it is in development. Competitors include statins, PCSK9 inhibitors, and other lipid-lowering therapies (e.g., Repatha (AMGN), Praluent (SNY)).
Market Dynamics
Industry Overview
The pharmaceutical industry focused on cardio-metabolic diseases is substantial and growing, driven by the increasing prevalence of conditions like hypercholesterolemia and cardiovascular disease globally. There is a high demand for novel therapies that can effectively manage lipid levels and reduce cardiovascular risk.
Positioning
NewAmsterdam Pharma is positioned as a potentially disruptive player in the lipid-lowering market with obicetrapib, offering a novel mechanism of action and oral administration. Their competitive advantage lies in the potential for superior LDL-cholesterol lowering compared to existing therapies.
Total Addressable Market (TAM)
The global lipid-lowering drug market is estimated to be worth over $30 billion annually. NewAmsterdam Pharma aims to capture a significant portion of this market with obicetrapib, targeting patients who are not adequately managed by existing therapies. It is estimated that the total addressable market will reach $50 billion by 2030.
Upturn SWOT Analysis
Strengths
- Novel mechanism of action (CETP inhibition)
- Oral administration
- Potentially superior LDL-cholesterol lowering
- Experienced management team
- Strong clinical trial results so far
Weaknesses
- Clinical trial risks
- Regulatory approval risks
- Commercialization challenges for a small company
- Dependence on a single drug candidate (obicetrapib)
- Requires significant funding to support ongoing clinical trials.
Opportunities
- Large and growing market for lipid-lowering therapies
- Potential to address unmet needs in high-risk patients
- Partnerships with larger pharmaceutical companies
- Expansion into other cardio-metabolic disease areas
- Potential for premium pricing due to novel mechanism of action
Threats
- Competition from existing therapies (statins, PCSK9 inhibitors)
- Development of new therapies by competitors
- Adverse events or safety concerns in clinical trials
- Regulatory hurdles and delays
- Pricing and reimbursement pressures
Competitors and Market Share
Key Competitors
- AMGN
- SNY
- NVO
Competitive Landscape
NewAmsterdam Pharma faces intense competition from established pharmaceutical companies with marketed lipid-lowering therapies. However, obicetrapib's novel mechanism of action could provide a competitive advantage.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by the advancement of obicetrapib through preclinical and clinical development stages.
Future Projections: Future growth depends on the successful completion of Phase 3 clinical trials, regulatory approval, and commercialization of obicetrapib. Analyst estimates will vary depending on the perceived probability of success. Expected market adoption rates will play a significant part in growth projections.
Recent Initiatives: Recent strategic initiatives include enrolling patients in Phase 3 clinical trials for obicetrapib and preparing for potential regulatory submissions.
Summary
NewAmsterdam Pharma is a clinical-stage biopharmaceutical company focused on a potentially revolutionary oral medicine. The company is currently in late-stage clinical trials. If successful, the company is well poised to capture significant market share. However, as with most pharmaceutical companies, there is significant risk in drug approval, and a large investment is still needed to keep it afloat and commercialize the drug.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data is based on publicly available information and may be subject to change. Investment decisions should be made based on individual risk tolerance and financial situation.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NewAmsterdam Pharma Company N.V. Ordinary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2022-11-23 | CEO, President, Executive Board Member & Director Dr. Michael Harvey Davidson FACC, Facp., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 77 | |
Full time employees 77 | |||
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.